Carregant...
Pembrolizumab-Induced Mobitz Type 2 Second-Degree Atrioventricular Block
Pembrolizumab is a monoclonal antibody directed towards programmed cell death protein 1 (PD-1) and is an antineoplastic drug which has a growing variety of oncologic uses. Pembrolizumab is commonly associated with immune-related adverse events (IRAEs) but is infrequently noted to cause cardiotoxicit...
Guardat en:
| Publicat a: | Case Rep Cardiol |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Hindawi
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7007942/ https://ncbi.nlm.nih.gov/pubmed/32047674 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2020/8428210 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|